肠道微生物在肝癌中的作用(综述)
创作:Dr.Smile 审核:Lexi 03月28日
  • 肠漏和菌群紊乱是慢性肝病(CLD)各阶段的重要特征,可促使CLD发展为肝纤维化、肝硬化、肝细胞癌(HCC);
  • 肠漏和菌群紊乱增加细菌代谢物和微生物相关分子模式(MAMPs)在肝脏的暴露,使其通过多种途径促进HCC发展;
  • 尚无证据表明肠道菌群是否调控小鼠或人类HCC中抗肿瘤免疫反应;
  • 肠道菌群可作为生物标志物用于HCC筛查和早期诊断;
  • 因其在慢性肝病发展中的作用及其与免疫系统的相互作用,肠道菌群被认为是预防和免疫治疗的重要靶点。
主编推荐语
Lexi
肝细胞癌(HCC)是全球癌症死亡的第三大原因,最新发表在Journal of Hepatology的综述文章回顾了肠道微生物在HCC中的作用。讨论了肠-肝轴在小鼠模型和患者中促进HCC发展的机制,包括生态失调、肠道渗漏和细菌代谢物,并特别关注非酒精性脂肪性肝病(NAFLD)作为HCC发展最快的诱因。此外,还回顾了近年来利用肠道菌群作为肝癌患者潜在的诊断工具和新的治疗靶点的研究进展,特别是在免疫治疗方面。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片

Gut microbiome in HCC – Mechanisms, diagnosis and therapy

肝细胞癌中的肠道微生物组——机制、诊断和治疗

10.1016/j.jhep.2019.08.016

02-01, Review

Abstract & Authors:展开

Abstract:收起
The microbiome exerts essential functions in health and disease, modulating key processes in metabolism, inflammation and immunity. Recent evidence has revealed a key role of the microbiome in carcinogenesis as well as anti-cancer immune responses in mouse models and patients. Herein, we will review functions of the gut microbiome in hepatocellular carcinoma (HCC), the third leading cause of worldwide cancer mortality. The majority of HCC develops in patients with chronic liver disease, caused by viral hepatitis, non-alcoholic fatty liver disease (NAFLD) and alcohol-related fatty liver disease. In this review, we will discuss mechanisms by which the gut-liver axis promotes the development of HCC in mouse models and patients, including dysbiosis, the leaky gut and bacterial metabolites, with a particular focus on NAFLD as the fastest growing cause of HCC development. Moreover, we will review recent progress in harnessing the gut microbiome as a potential diagnostic tool and novel therapeutic target in patients with HCC, in particular in the setting of immunotherapy.

First Authors:
Robert F Schwabe

Correspondence Authors:
Robert F Schwabe,Tim F Greten

All Authors:
Robert F Schwabe,Tim F Greten

评论